Published: 17 January 2022
Author(s): Christian Labenz, Gerrit Toenges, Ming-Hua Zheng, Dora Ding, Robert P. Myers, Peter R. Galle, Angelo Armandi, Javier Ampuero, Manuel Romero Gómez, Elisabetta Bugianesi, Quentin M. Anstee, Jörn M. Schattenberg
Issue: April 2022
Section: Original article

Non-alcoholic fatty liver disease (NAFLD) has become a major health burden [1]. Among the large group of patients that are affected, the subgroup progressing to end-stage disease exhibits the highest mortality and health expenses [2,3].

Newsletters

Stay informed on our latest news!